Clinical trials: Hot Flashes
Vasomotor Symptoms, Hot Flashes
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.
- Trial name
- NCT00446199
- Testing
- 0.5mg DRSP / 0.5mg E2 (BAY86-4891), 0.25mg DRSP / 0.5mg E2 (BAY86-4891), Estradiol (E2 0.3mg)
- Where
- 76 sites in United States
- Volunteers
- 735 people
- Sponsor
- Bayer
Prostate Cancer, Hot Flashes
(SGB) in Men Treated for Prostate Cancer Improve Hot Flashes
Androgen Deprivation Therapy (ADT) is a critical component of advanced prostate cancer treatment but causes numerous adverse effects including decreased bone mass, decreased muscle mass, gynecomastia, erectile dysfunction, loss…
- Trial name
- NCT03796195
- Testing
- .5% Bupivacaine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Hot Flashes, Hot Flushes
Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer
Vasomotor symptoms (hot flashes, night sweats, VMS) affect up to 65% of breast cancer survivors and negatively impact their quality of life.
- Conditions
- Hot Flashes, Hot Flushes, Vasomotor Symptoms
- Trial name
- NCT03122301
- Testing
- Stellate Ganglion Block injection with bupivicaine, Saline
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwestern University
Menopausal and Female Climacteric States
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
The purpose of this study is to determine whether GSK232802 is safe and effective in reducing the frequency and severity of hot flashes associated with menopause.
- Trial name
- NCT00604825
- Testing
- GSK232802, PREMARIN
- Where
- 87 sites in United States, Argentina and 7 more
- Volunteers
- 356 people
- Sponsor
- GlaxoSmithKline
Hot Flushes
Vilazodone for Menopausal Hot Flashes
This is a pilot study to determine proof in principle that vilazodone, a selective serotonin reuptake inhibitor and 5HT1a agonist, reduces the frequency and severity of menopausal hot flashes relative to placebo.
- Trial name
- NCT01680900
- Testing
- vilazodone
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Pennsylvania
Hot Flashes
Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women
Depomed's Gabapentin Extended Release is an investigational, extended release formulation of Gabapentin that is being studied for the treatment of Hot Flashes/Hot Flushes in postmenopausal women
- Trial name
- Breeze3 (NCT01080300)
- Testing
- Gabapentin Extended Release
- Where
- 66 sites in United States
- Volunteers
- 600 people
- Sponsor
- Depomed
Healthy, no Evidence of Disease, Hot Flashes
Evaluation of SAMe for Hot Flashes
RATIONALE: S-adenosyl-L-methionine may help relieve hot flashes in women based upon its ability to potentially modulate serotonin.
- Trial name
- SAMe (NCT01140646)
- Testing
- S-adenosyl-L-methionine disulfate p-toluene-sulfonate, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Postmenopausal Symptoms
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate) Capsules 7.5 mg when given as a single dose and…
- Trial name
- N30-005 (NCT01829919)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Noven Therapeutics
Vasomotor Symptoms, Menopausal Symptoms
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)
A two-part study designed to evaluate the effect of Estetrol (E4) 15 mg, 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) in the Efficacy Study Part and the safety of E4 20 mg in the Safety Study Part.
- Trial name
- E4Comfort II (NCT04090957)
- Testing
- Estetrol oral tablet
- Where
- 117 sites in United States, Canada
- Volunteers
- 1,015 people, healthy volunteers welcome
- Sponsor
- Estetra
Menopause, Multiple Sclerosis
A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
Duavee is a hormone receptor modulator that has been approved for the treatment of menopausal symptoms in menopausal women. The goal of this 8-week randomized, double blind, placebo controlled pilot study, is to determine whether…
- Trial name
- MS-TSEC (NCT02710214)
- Testing
- Tissue Selective Estrogen Complex
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Hot Flushes, Night Sweats
Progesterone for Perimenopausal Night Sweats
The purpose of this study is to test whether a oral micronized progesterone reduces the Vasomotor Symptom Score comprised of the number and severity of hot flushes and night sweats in perimenopausal women.
- Trial name
- NCT01464697
- Testing
- Oral micronized progesterone
- Where
- Canada
- Volunteers
- 249 people
- Sponsor
- University of British Columbia
Hot Flashes
Wrist Cooling for Hot Flashes Clinical Trial
This pilot study aims to determine the impact of an experimental active cooling wrist device compared to a placebo device [the devices look identical] on symptom control of hot flashes in adult men and adult women experiencing…
- Trial name
- NCT05595213
- Testing
- Active cooling device with cooling plate, Hot Flash Diary
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Boston University
Hot Flashes
A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women
The purpose of this study is to determine whether RAD1901 is effective in decreasing hot flashes in postmenopausal women.
- Trial name
- NCT00875420
- Testing
- RAD1901
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Menopause, Hot Flashes
Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women
The broad goal of this study is to obtain pilot data to determine the tolerability and preliminary efficacy of the non-hormonal agent gabapentin for insomnia symptoms and nighttime vasomotor Symptoms (VMS) when open-label…
- Conditions
- Menopause, Hot Flashes, Vasomotor Disturbance
- Trial name
- NCT02040532
- Testing
- Gabapentin
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Hot Flashes
Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
This study evaluates the efficacy, safety, tolerability, and pharmacokinetics of once daily SJX-653 in postmenopausal women with moderate to severe VMS.
- Trial name
- NCT04278872
- Testing
- SJX-653
- Where
- 22 sites in Belgium, Germany and 2 more
- Volunteers
- 13 people
- Sponsor
- Sojournix, Inc.
Depression
Omega-3 for Peri- and Postmenopausal Depression
The purpose of this study is to determine if an eight-week intervention with omega-3 fatty acids significantly reduces depressive symptoms in symptomatic peri- and postmenopausal women.
- Trial name
- O3Meno (NCT00825994)
- Testing
- Omega-3 Fatty Acids
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Massachusetts General Hospital
Postmenopause
Endometrial Safety Study
The study is designed to investigate the safety of the investigational product for the lining of the uterus (endometrium).
- Trial name
- NCT00522873
- Testing
- 0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
- Where
- 59 sites in United States, Argentina and 6 more
- Volunteers
- 662 people
- Sponsor
- Bayer
Hot Flashes
Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial
This study is designed to determine the effect of a Hypnosis Intervention on reducing hot flash frequency (perceived impact vs. physiologically measured impact), severity and daily interference in post-menopausal women.
- Trial name
- NCT01293695
- Testing
- Hypnosis, Structured attention
- Where
- United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Baylor University
Menopausal Flushing
Neuropeptide Treatment for Hot Flushes During the Menopause
Placebo-controlled, double-blinded, cross-over clinical trial of a new investigational product
- Trial name
- NK3R (NCT02668185)
- Testing
- NK3R antagonist - AZD4901
- Where
- United Kingdom
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Postmenopausal Symptoms
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
The purpose of this study is to assess the safety \& efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause.
- Trial name
- N30-003 (NCT01361308)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- 74 sites in United States
- Volunteers
- 614 people
- Sponsor
- Noven Therapeutics